“…The increase in the aPTT (34-59 s), ECT (33-69 s), thrombin time (TT) (>120 s), and ETP (2.9-7.5 min) after starting dabigatran was not reversed by the PCC4 (14). In an ex vivo analysis, FEIBA (20,40,80, and 160 U/kg equivalent) and a PCC4 PCC Kanokad (Laboratoire Français des Biotechnologies, Courtaboeuf, France) [12.5, 25, and 50 units/kg equivalent] demonstrated a dose-related correction in the ETP compared with rFVIIa (20, 60, and 120 mcg/kg equivalent), with FEIBA being the only agent to correct all thrombin generation times (17). Although in early stages of development, an antibody to dabigatran is being investigated (19).…”